Clinical trials: Ameloblastoma
Odontogenic Cysts, Odontogenic Tumors
Evaluation of the Expression and Prognostic Role of Tumor Stem Cell Marker SOX2 in Odontogenic Cysts and Tumors
The pathogenesis of odontogenic lesions remains unclear; however, a probable explanation may involve the existence of tumor stem cells (TSCs), which are thought to generate both benign and malignant tumors.
- Trial name
- NCT06833840
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- Mansoura University
Ameloblastoma, BRAF V600E Mutation Positive
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
This study aims to evaluate the tumor shrinkage effect of preoperative targeted induction therapy with dabrafenib and trametinib in patients with conventional ameloblastoma harboring the BRAF V600E mutation.
- Trial name
- NETCAM (NCT06653517)
- Testing
- Dabrafenib, Trametinib
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Ameloblastoma
Virtual Lesion Segmentation and Mandibular Ameloblastoma Radiographic Safety Margin
Reconstruction of segmental mandibular defects is in a continuous state of evolution utilizing the recent advances in Computer-Aided Designing (CAD) and preoperative Virtual Surgical Planning (VSP).
- Trial name
- NCT07306962
- Testing
- Virtual lesion segmentation for mandibular ameloblastoma
- Where
- Egypt
- Volunteers
- 10 people
- Sponsor
- Alexandria University
Ameloblastoma
Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma
This pilot clinical trial plans to carry out dabrafenib adjuvant therapy combined with lesion curettage after fenestrated decompressive surgery for BRAF mutation-positive multicystic ameloblastoma to explore the effectiveness of…
- Trial name
- NCT06264778
- Testing
- Dabrafenib
- Volunteers
- 10 people
- Sponsor
- Shandong University
Ameloblastoma
Effect of Tetracycline Socked Pack on Acceleration of Healing During Marsupialization
Ameloblastoma is an epithelial odontogenic tumor. Although ameloblastoma is classified as a benign tumor, it is locally invasive with high recurrence rate. It accounts for up to 18 % of all oral and odontogenic tumors.
- Trial name
- NCT06759610
- Testing
- Tetracyclin
- Where
- Egypt
- Volunteers
- 14 people
- Sponsor
- Minia University
Ameloblastoma, BRAF Gene Mutation
Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
This pilot clinical trial studies dabrafenib and trametinib in treating patients with ameloblastoma and a specific mutation (change) in the BRAF gene.
- Trial name
- NCT02367859
- Testing
- Dabrafenib, Trametinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Stanford University
Cystic Cavity Area Reduction Efficiency, the Recurrence of the Tumor
Clinical Evaluation of Fenestration Decompression Combined With Secondary Curettage for Ameloblastoma of the Jaw: Retrospective Radiographic Analysis
Objectives: To investigate the outcomes of fenestration decompression combined with secondary curettage (FDSC) in the surgical treatment of jaw ameloblastoma.
- Trial name
- NCT04987515
- Testing
- fenestration decompression combined with secondary curettage
- Volunteers
- 233 people, healthy volunteers welcome
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Ameloblastoma
Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma
Ameloblastoma is the most common benign odontogenic tumor, characterized by high local invasiveness and a high recurrence rate. Currently, surgical treatment is the standard treatment modality.
- Trial name
- NETCAM-RCT (NCT06819605)
- Testing
- Dabrafenib and trametinib (combination)
- Volunteers
- 46 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Osteofibrous Dysplasia
Osteofibrous Dysplasia (Kempson-Campanacci's Disease)
The aim of the present study is to obtain long term follow-up in patients with osteofibrous dysplasia, to assess natural history of the disease, late results of treatment and in particular the potential and risk of progression to…
- Trial name
- DOFOL (NCT04104763)
- Testing
- study of osteofibrous dysplasia features
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Istituto Ortopedico Rizzoli